Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3095-3100

  Raj, Ganesh V ^a   Iasonos, Alexia ^a   Herr, Harry ^a   Donat, Sherri Machele ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; DOXORUBICIN; METHOTREXATE; VINBLASTINE; ANTINEOPLASTIC AGENT; M VAC PROTOCOL; M-VAC PROTOCOL;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLADDER TUMOR; DRUG EFFECT; KIDNEY; METABOLISM; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PREDICTION AND FORECASTING; THEORETICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; CREATININE; DOXORUBICIN; ELIGIBILITY DETERMINATION; FEMALE; HUMANS; KIDNEY; MALE; METHOTREXATE; MIDDLE AGED; MODELS, THEORETICAL; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 33746023301     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.3091     Document Type: Article

References (20)

1. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003
2. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202-206, 2005
3. Neoadjuvant chemotherapy for invasive bladder cancer. Oxford, United Kingdom, Cochrane Library, CD005246, 18:2005
4. Pectasides D, Pectasides M, Nikolaou M: Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: Literature review. Eur Urol 48:60-68, 2005
5. Bellmunt J, Ribas A, Eres N, et al: Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966-1972, 1997
6. Beck CL, Pucino F, Carlson JD, et al: Evaluation of creatinine clearance estimation in an elderly male population. Pharmacotherapy 8:183-188, 1988
7. Malmrose LC, Gray SL, Pieper CF, et al: Measured versus estimated creatinine clearance in a high-functioning elderly sample: MacArthur Foundation Study of Successful Aging. J Am Geriatr Soc 41:715-721, 1993
8. Markantonis S, Agathokleous-Kioupaki E: Can two-, four- or eight-hour urine collections after voluntary voiding be used instead of twenty-four-hour collections for the estimation of creatinine clearance in healthy subjects? Pharm World Sci 20:258-263, 1998
9. von der Maase H: Current and future perspectives in advanced bladder cancer: Is there a new standard? Semin Oncol 29:3-14, 2002
10. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
11. von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608, 2005
12. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration: Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 48:189-201, 2005
13. Fossa SD, Skovlund E: Selection of patients may limit the generalizability of results from cancer trials. Acta Oncol 41:131-137, 2002
14. Spinler SA, Nawarskas JJ, Boyce EG, et al: Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Iohexol Cooperative Study Group. Ann Pharmacother 32:1275-1283, 1998
15. Sternberg CN, Yagoda A, Scher HI, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139:461-469, 1988
16. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999
17. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
18. Hershman D, Jacobson JS, McBride R, et al: Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 94:540-549, 2004
19. Bamias A, Efstathiou E, Moulopoulos LA, et al: The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 16:307-313, 2005
20. Hussain SA, Stocken DD, Riley P, et al: A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 91:844-849, 2004